<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01235468</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-10-7959-AN-CTIL</org_study_id>
    <nct_id>NCT01235468</nct_id>
  </id_info>
  <brief_title>Allogenic Transplantation of Ex-vivo Expanded Cord Blood (CB)</brief_title>
  <official_title>Allogenic Transplantation of Ex-vivo Expanded CB Progenitors for Haematological Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Avichai Shimoni MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the safety profile and tolerability of infusion of cord
      blood cells expanded in the lab and to evaluated whether through the infusion of expanded
      cells it is possible to expedite engraftment time after transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stem cell transplantation is a curative approach for patients with hematological
      malignancies. Umbilical cord blood is a source of stem cells for transplantation in patients
      with no related donor. However, in adults, the number of stem cells in a single unit, may be
      too low to allow engraftment, and the time to engraftment may be prolonged, increasing the
      risks of the transplant. In this study, we expand part of the cord blood unit, in the lab,
      trying to increase unit size, such that it would be suitable for adults, and would allow safe
      engraftment.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    loss of support
  </why_stopped>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>1 month</time_frame>
    <description>Number of patients with adverse events during infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>engraftment</measure>
    <time_frame>3 months</time_frame>
    <description>Time to engraftment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>treatment-related toxicity</measure>
    <time_frame>3 months</time_frame>
    <description>Type and severity of adverse events after transplantation using the NCI CTC scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GVHD</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients with acute and chronic GVHD after transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunological reconstruction</measure>
    <time_frame>5 years</time_frame>
    <description>immunological reconstruction after transplantation measured by lymphocyte number and function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse</measure>
    <time_frame>5 years</time_frame>
    <description>rate of disease recurrence</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Umbilical Cord Blood</condition>
  <condition>Stem Cell Transplantation</condition>
  <condition>Hematological Malignancies</condition>
  <arm_group>
    <arm_group_label>CB expnasion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ex-vivo expansion of cord blood for transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ex vivo expansion</intervention_name>
    <description>ex-vivo expansion of cord blood for transplantation</description>
    <arm_group_label>CB expnasion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  hematological malignancy

          -  standard indication for allogeneic transplantation

          -  expected survival time over 12 weeks

          -  no related or unrelated donor

          -  availability of a cord blood unit of compatible placental blood cryopreserved in at
             least 2 different bags; one of the two units should have a cellular content at least
             equal to the minimum dose of 2 x 107 nucleated cells per kilogram of body weight

        Exclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status &gt;2

          -  Prior allogeneic transplantation

          -  Pregnant or nursing women

          -  Positive serology for hepatitis B or C

          -  HIV positive

          -  Left ventricular ejection fraction &lt; 50%

          -  DLCO &lt; 50%

          -  Psychiatric, addictive, or any disorder/disease which compromises ability to give
             informed consent for participation in this study

          -  Treatment with other investigational drugs within 4 weeks of enrolling in this
             protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnon Nagler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chaim Sheba Medical Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>Israel</country>
    <country>Italy</country>
  </removed_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2010</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Avichai Shimoni MD</investigator_full_name>
    <investigator_title>Dr. Avichai Shimoni, hematologist</investigator_title>
  </responsible_party>
  <keyword>umbilical cord blood</keyword>
  <keyword>ex vivo expansion</keyword>
  <keyword>engraftment</keyword>
  <keyword>GVHD</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

